• Explore /
  • Poster
  • / Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.

Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.

Abstract Poster

Authors

null

Suzanne George

Dana-Farber Cancer Institute, Boston, MA

Suzanne George , Michael C. Heinrich , John Raymond Zalcberg , Sebastian Bauer , Hans Gelderblom , Patrick Schoffski , Cesar Serrano , Robin L. Jones , Steven Attia , Gina Z. D'Amato , Ping Chi , Peter Reichardt , Mario E. Lacouture , Elva Cha , Julie Nicole Meade , Rodrigo Ruiz-Soto , Jean-Yves Blay , Margaret von Mehren

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Gastrointestinal Stromal Tumors (GIST)

Clinical Trial Registration Number

NCT03353753

Citation

J Clin Oncol 38: 2020 (suppl; abstr 11539)

DOI

10.1200/JCO.2020.38.15_suppl.11539

Abstract #

11539

Poster Bd #

427

Abstract Disclosures

Similar Posters

First Author: Steven Bialick

First Author: Suzanne George

First Author: Michael C. Heinrich

First Author: Margaret von Mehren